Textiles functionalized with antiviral agents are intended to reduce the risk of transmission of pathogens, particularly in a medical environment. These antiviral properties must be carefully tested and verified in laboratory tests. The biological testing laboratory of the German Institutes of Textile and Fiber Research Denkendorf has examined antiviral activities with coronaviruses as part of a research project on textiles for infection control.

With the aid of physical forces it is possible to actively steer the formation of engineered tissue. For example, sound waves can be used to create functional vascular networks with blood vessel-like structures in vitro. Scientists at the Center for Molecular Biology of Heidelberg University have demonstrated this through their methodology for acoustic manipulation.

Chronic inflammatory bowel diseases - 25/09/2024

Proinflammatory regulatory T lymphocytes as a therapeutic target in Crohn's disease

Chronic inflammatory bowel diseases are very stressful for those affected and increase the risk of bowel cancer. PD Dr. Robyn Laura Kosinsky from the Bosch Health Campus in Stuttgart, together with researchers from the USA, identified disfunctional regulatory T cells as important drivers of inflammation in Crohn's disease. They also found that with the help of an epigenetically active drug, it was possible to restore the cells’ original…

A research team from Freiburg and Frankfurt has discovered how cells recognise and internally break down waste. The results are relevant for the development of therapies for diseases such as Alzheimer’s.

Targeted molecular interventions in the replication cycle and the immune recognition of viruses are intended to prevent viral entry into cells and virus replication. Scientists work on new approaches to combating highly dangerous viral diseases such as yellow fever or Lassa fever. The European Union is supporting the project over a period of five years to the tune of just under eight million euros.

While broad-spectrum antibiotics can offer protection against a wide variety of bacteria, there are currently no analogous clinically available broad-spectrum antiviral agents that can act on several different viruses. An international research team has now shown that polystyrene sulfonate (PSS), a negatively charged polymer, has the potential to be used in the prevention of viral infections – not only in the fight against the SARS-CoV-2 and cold…

Mutations of the tumor suppressor p53 not only have a growth-promoting effect on the cancer cells themselves, but also influence the cells in the tumor's microenvironment. Scientists at the Weizmann Institute in Israel and at the German Cancer Research Center (DKFZ) have now shown that p53-mutated mouse breast cancer cells reprogram fat cells.

Tumour organoids facilitate drug discovery - 20/07/2023

Drug screening for children with cancer using patient-specific miniature tumours

Standard drugs often don’t work in children and adolescents with recurrent cancer. Researchers from the Hopp Children's Tumour Centre (KITZ) and the German Cancer Research Center (DKFZ) in Heidelberg have been looking to open up new therapy options for those affected, and have cultivated individual miniature tumours from biopsy samples to test the effectiveness of a variety of drugs within a few weeks.

Project BlindZero - 03/08/2023

Hope for patients with eye diseases: human cornea from 3D printers

Thousands of cornea transplants are performed every year. However, donors are rare and the procedure is not always without complications. Researchers at the University of Heidelberg are developing an innovative technique in the project BlindZero. It involves ‘printing’ human corneas directly onto patients’ eyes using 3D bioprinting. The reprogrammed genetically engineered cells used for this purpose are not expected to cause a rejection reaction.

Stem cell research - 14/03/2024

Using organoids to gain a better clinical understanding of pancreatic cancer

Prof. Dr. Alexander Kleger carries out translational research at Ulm University Hospital to gain a better understanding of pancreatic ductal adenocarcinoma (PDAC) and develop individualised treatments. He and his team are using organoid models and stem cell-based systems and have succeeded in simultaneously cultivating all three main cell types of the pancreas from pluripotent stem cells.

Chordomas are rare bone tumors for which there are no effective drugs. A research team from the DKFZ and the NCT Heidelberg has now developed a promising approach: Tailor-made mini-proteins specifically block the driver of tumor development. In the result, slowing the growth of chordoma cells in the laboratory and in a mouse model, while also revealing further molecular vulnerabilities of the tumor that could be addressed with approved drugs.

Prof. Dr. Peter Loskill and Dr. Silke Riegger from the 3R Center Tübingen for in-vitro models and animal testing alternatives have been awarded the Ursula M. Händel Animal Welfare Prize 2024. The prize, endowed with 80,000 euros, was awarded to them in Würzburg for the development of organ-on-chip (OoC) systems as an alternative to animal testing.

Animal-free testing of chemicals and cosmetics - 07/05/2025

Human reporter skin for visualsing skin reactions

Before new cosmetics can be placed on the market, all ingredients must undergo rigorous testing for safety and efficacy. Dr. Anke Burger-Kentischer of the Fraunhofer IGB has long been at the forefront of animal-free research and has developed an innovative method to quickly and reliably test cosmetics and other chemicals without using animals. She was awarded the 2024 Hamburg Research Prize for her groundbreaking ‘reporter skin’ in vitro model.

Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have developed antibodies that have two antigen-binding sites and can couple cancer cells with effector cells of the immune system. In laboratory tests, these bridging antibodies, together with an enhancer antibody, were able to specifically mobilize the body's own immune defenses and destroy breast cancer cells.

Stem cell-like leukemia cells are responsible for relapses in children and adolescents with a certain type of blood cancer, T-ALL. Researchers at the Hopp Children's Cancer Center Heidelberg (KiTZ), the Molecular Medicine Partnership Unit and the German Cancer Research Center were able to show this in a study. The results could help to overcome resistance in this form of blood cancer and prevent relapses.

A new network has been set up in Baden-Württemberg aimed at reducing animal experiments as well as further improving animal welfare. It combines new approaches and measures at the state’s biomedical research locations, which are expected to limit stress in laboratory animals and steadily reduce the number of animals used in research in line with the 3R principles of Replacement, Reduction, and Refinement.

Bacteria of the species Pseudomonas aeruginosa are antibiotic-resistant hospital germs that can enter blood, lungs and other tissues through wounds and cause life-threatening infections. In a joint project, researchers from the Universities of Freiburg and Strasbourg in France have discovered a mechanism that likely contributes to the severity of P. aeruginosa infections.

CAR-T cell therapies have proven successful in treating several types of blood and lymphoid cancers. However, their use in treating other tumors is significantly more challenging, in part because suitable target structures are lacking.

Certain childhood tumors have an extreme need for amino acids. Scientists at the Hopp Children's Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ), the University of Heidelberg, and HI-STEM* gGmbH have now discovered the molecular mechanisms underlying this and how the cancer cells could be turned off.

Neurosciences - 28/02/2024

Mesh microelectrode arrays: research with brain organoids on a new level

How does the brain work? Brain organoids are derived from pluripotent stem cells and regarded as valuable model systems that can depict some aspects of neurological functioning. Dr. Peter Jones from NMI together with Dr. Thomas Rauen from the MPI for Molecular Biomedicine in Münster, has taken organoid research to a new level. His novel mesh microelectrode array (Mesh-MEA) greatly improves the growth and electrophysiological analysis of tissue.

Using animal-free methods to assess the hazard potential of chemicals to the nervous system of unborn children? An international research team including toxicologists from Konstanz and Düsseldorf has developed a testing battery based on human cells that has the potential to replace traditional methods for assessing developmental neurotoxicity.

Researchers from the Medical Faculty Heidelberg, the Medical Faculty Mannheim, and the Centre for Organismal Studies at Heidelberg University have launched a new research project investigating so-called dipeptides. The consortium aims to determine which dipeptides have the strongest protective effects and how they could be harnessed in future therapies for vascular and kidney diseases.

Dossier - 14/06/2016

CRISPR/Cas – genome editing is becoming increasingly popular

The number of publications and patents that involve the CRISPR/Cas system has been increasing exponentially since the technique was first described a few years ago. The increase in funding for projects involving CRISPR/Cas also demonstrates how powerful this new method is. The targeted modification of genomes (also called gene or genome editing) using CRISPR/Cas is extraordinarily accurate and also has the potential to cure hereditary diseases.

Joint press release of the Heidelberg Faculty of Medicine at Heidelberg University and the German Center for Infection Research: With the FDA approval of Hepcludex (bulevirtide), a therapy for chronic hepatitis D developed at the Heidelberg Faculty of Medicine at Heidelberg University, Heidelberg University Hospital, and the German Center for Infection Research (DZIF) has now reached the world’s most important pharmaceutical market.

Cell-based solution in place of animal testing - 05/06/2025

Innovative cell-based test to detect pyrogens in drugs

Drug safety testing for microbial contaminants and fever-inducing substances (pyrogens) still frequently uses animal experiments. InnoZell, a start-up that will soon be spun off from the University of Konstanz, has developed a compelling alternative: an animal-free, human cell-based assay that is faster, more sensitive and more reliable than traditional methods – and can be customised to meet user-specific needs.